title: [The safety of tadalafil in the treatment of erectile dysfunction].
abstract: The cyclic nucleotide (cGMP) signalling pathway mediates the smooth-muscle relaxing effects of nitric oxide necessary for normal erectile function. Down-regulation of this pathway is the pathophysiological pivot of many forms of erectile dysfunction (ED) and leads to the development of some chronic diseases, such as hypertension and type 2 diabetes mellitus. Therefore, selective inhibition of the enzyme that catalyses the degradation of cGMP promotes erectile responses to sexual stimulation. Recently, a new phosphodiesterase type 5 (PDE-5) inhibitor tadalafil has emerged, which has a prolonged half-life. Here is a review of recent studies on the safety of tadalafil in the treatment of ED.
authors.affiliation: Department of Reproduction & Genetics, PLA Research Institute of Clinical Laboratory Medicine, Nanjing General Hospital of Nanjing Command, PLA, Nanjing, Jiangsu 210002, China.
authors.forename: Hao-yang
authors.initials: HY
authors.lastname: Wang
authors.forename: Yu-feng
authors.initials: YF
authors.lastname: Huang
mesh_terms: D001416:Back Pain / Q000139:chemically induced; D002243:Carbolines / Q000009:adverse effects / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000068581:Tadalafil
chemical_list: D002243:Carbolines; D010726:Phosphodiesterase Inhibitors; D000068581:Tadalafil